127 related articles for article (PubMed ID: 7514357)
1. CD34 immunohistochemistry of bone marrow biopsies: prognostic significance in primary myelodysplastic syndromes.
Soligo DA; Oriani A; Annaloro C; Cortelezzi A; Calori R; Pozzoli E; Nosella D; Orazi A; Deliliers GL
Am J Hematol; 1994 May; 46(1):9-17. PubMed ID: 7514357
[TBL] [Abstract][Full Text] [Related]
2. CD34 immunohistochemical staining of bone marrow biopsies in myelodysplastic syndromes.
Min YH; Lee ST; Min DW; Kim TS; Lee CH; Lee BK; Hahn JS; Ko YW
Yonsei Med J; 1995 Mar; 36(1):1-8. PubMed ID: 7537931
[TBL] [Abstract][Full Text] [Related]
3. Primary myelodysplastic syndromes: diagnostic and prognostic significance of immunohistochemical assessment of bone marrow biopsies.
Mangi MH; Mufti GJ
Blood; 1992 Jan; 79(1):198-205. PubMed ID: 1370203
[TBL] [Abstract][Full Text] [Related]
4. CD34/QBEND10 immunostaining in bone marrow biopsies: an additional parameter for the diagnosis and classification of myelodysplastic syndromes.
Baur AS; Meugé-Moraw C; Schmidt PM; Parlier V; Jotterand M; Delacrétaz F
Eur J Haematol; 2000 Feb; 64(2):71-9. PubMed ID: 10997326
[TBL] [Abstract][Full Text] [Related]
5. Prognostic evaluation of ALIP and CD34 immunostaining in IPSS-R subgroups of myelodysplastic syndromes.
Xiong B; Nie Y; Tang Z; Xue M; Zuo X
Pathology; 2017 Aug; 49(5):526-533. PubMed ID: 28669578
[TBL] [Abstract][Full Text] [Related]
6. Identification of CD34+ cells in normal and pathological bone marrow biopsies by QBEND10 monoclonal antibody.
Soligo D; Delia D; Oriani A; Cattoretti G; Orazi A; Bertolli V; Quirici N; Deliliers GL
Leukemia; 1991 Dec; 5(12):1026-30. PubMed ID: 1723130
[TBL] [Abstract][Full Text] [Related]
7. Apparent expansion of CD34+ cells during the evolution of myelodysplastic syndromes to acute myeloid leukemia.
Span LF; Dar SE; Shetty V; Mundle SD; Broady-Robinson L; Alvi S; Raymakers RA; de Witte T; Raza A
Leukemia; 1998 Nov; 12(11):1685-95. PubMed ID: 9823942
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical detection of vascular endothelial growth factor (VEGF) in the bone marrow in patients with myelodysplastic syndromes: correlation between VEGF expression and the FAB category.
Wimazal F; Krauth MT; Vales A; Böhm A; Agis H; Sonneck K; Aichberger KJ; Mayerhofer M; Simonitsch-Klupp I; Müllauer L; Sperr WR; Valent P
Leuk Lymphoma; 2006 Mar; 47(3):451-60. PubMed ID: 16396768
[TBL] [Abstract][Full Text] [Related]
9. Bone marrow histology and CD34 immunostaining in the prognostic evaluation of primary myelodysplastic syndromes.
Oriani A; Annaloro C; Soligo D; Pozzoli E; Cortelezzi A; Lambertenghi Deliliers G
Br J Haematol; 1996 Feb; 92(2):360-4. PubMed ID: 8603000
[TBL] [Abstract][Full Text] [Related]
10. QBEND10 for the diagnosis of myelodysplastic syndromes in routinely processed bone marrow biopsy specimens.
Horny HP; Wehrmann M; Schlicker HU; Eichstaedt A; Clemens MR; Kaiserling E
J Clin Pathol; 1995 Apr; 48(4):291-4. PubMed ID: 7542289
[TBL] [Abstract][Full Text] [Related]
11. Bone marrow biopsy in myelodysplastic syndromes: morphological characteristics and contribution to the study of prognostic factors.
Ríos A; Cañizo MC; Sanz MA; Vallespí T; Sanz G; Torrabadella M; Gomis F; Ruiz C; San Miguel JF
Br J Haematol; 1990 May; 75(1):26-33. PubMed ID: 2375920
[TBL] [Abstract][Full Text] [Related]
12. Additional prognostic value of bone marrow histology in patients subclassified according to the International Prognostic Scoring System for myelodysplastic syndromes.
Verburgh E; Achten R; Maes B; Hagemeijer A; Boogaerts M; De Wolf-Peeters C; Verhoef G
J Clin Oncol; 2003 Jan; 21(2):273-82. PubMed ID: 12525519
[TBL] [Abstract][Full Text] [Related]
13. Prognostic factors in the myelodysplastic syndromes: importance of initial data on peripheral blood counts, bone marrow cytology, trephine biopsy and chromosomal analysis.
Tricot G; Vlietinck R; Boogaerts MA; Hendrickx B; De Wolf-Peeters C; Van den Berghe H; Verwilghen RL
Br J Haematol; 1985 May; 60(1):19-32. PubMed ID: 3859319
[TBL] [Abstract][Full Text] [Related]
14. Maturation-associated immunophenotypic abnormalities in bone marrow B-lymphocytes in myelodysplastic syndromes.
Ribeiro E; Matarraz Sudón S; de Santiago M; Lima CS; Metze K; Giralt M; Saad ST; de Matos AO; Lorand-Metze I
Leuk Res; 2006 Jan; 30(1):9-16. PubMed ID: 16005514
[TBL] [Abstract][Full Text] [Related]
15. Risk assessment in myelodysplastic syndromes: value of clinical, hematologic and bone marrow histologic findings at presentation.
Morra E; Lazzarino M; Castello A; Inverardi D; Coci A; Alessandrino EP; Brusamolino E; Bernasconi P; Orlandi E; Bonfichi M
Eur J Haematol; 1990 Aug; 45(2):94-100. PubMed ID: 2209826
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of apoptosis as a prognostic factor in myelodysplastic syndromes.
Shimazaki K; Ohshima K; Suzumiya J; Kawasaki C; Kikuchi M
Br J Haematol; 2000 Sep; 110(3):584-90. PubMed ID: 10997968
[TBL] [Abstract][Full Text] [Related]
17. Life expectancy in primary myelodysplastic syndromes: a prognostic score based upon histopathology from bone marrow biopsies of 569 patients.
Maschek H; Gutzmer R; Choritz H; Georgii A
Eur J Haematol; 1994 Nov; 53(5):280-7. PubMed ID: 7813708
[TBL] [Abstract][Full Text] [Related]
18. High-level CD34 expression on megakaryocytes independently predicts an adverse outcome in patients with myelodysplastic syndromes.
Tang G; Wang SA; Menon M; Dresser K; Woda BA; Hao S
Leuk Res; 2011 Jun; 35(6):766-70. PubMed ID: 21367453
[TBL] [Abstract][Full Text] [Related]
19. Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases.
Orazi A
Pathobiology; 2007; 74(2):97-114. PubMed ID: 17587881
[TBL] [Abstract][Full Text] [Related]
20. Expression of the multidrug resistance P-glycoprotein and its relationship to hematological characteristics and response to treatment in myelodysplastic syndromes.
Lepelley P; Soenen V; Preudhomme C; Lai JL; Cosson A; Fenaux P
Leukemia; 1994 Jun; 8(6):998-1004. PubMed ID: 7516032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]